{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.9","upperLimit":"7.5","value":"7.3"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"5.7","value":"5.3"},{"groupId":"OG002","lowerLimit":"4.5","upperLimit":"5.7","value":"5.5"},{"groupId":"OG003","lowerLimit":"4.2","upperLimit":"5.7","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"294"},{"groupId":"OG002","value":"238"},{"groupId":"OG003","value":"248"}],"units":"Participants"}],"description":"Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.\n\nProgressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with wild-type KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG000","title":"Wild-type KRAS - Panitumumab Plus FOLFIRI"},{"description":"Participants with wild-type KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG001","title":"Wild-type KRAS - FOLFIRI Alone"},{"description":"Participants with mutant KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG002","title":"Mutant KRAS - Panitumumab Plus FOLFIRI"},{"description":"Participants with mutant KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG003","title":"Mutant KRAS - FOLFIRI Alone"}],"paramType":"MEDIAN","populationDescription":"KRAS Efficacy Analysis Set","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months","title":"Time to Disease Progression","type":"SECONDARY","unitOfMeasure":"months"}